Arteriovenous Malformations Market Report 2026

The arteriovenous malformations market size has grown strongly in recent years. It will grow from $3.1 billion in 2025 to $3.33 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to improvements in neuroimaging technologies, increased clinical awareness of avm conditions, expansion of specialized neurosurgical centers, adoption of endovascular embolization techniques, growth of hospital-based neurological care.

The arteriovenous malformations market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in neurovascular research, expansion of minimally invasive treatment adoption, growing focus on personalized treatment planning, increasing availability of advanced interventional devices. Major trends in the forecast period include increasing adoption of advanced neuroimaging diagnostics, rising use of minimally invasive endovascular treatments, growing focus on early and accurate diagnosis, expansion of multidisciplinary treatment approaches, enhanced monitoring of post-treatment outcomes.

The increasing preference for minimally invasive procedures is expected to drive the growth of the arteriovenous malformations market in the coming years. Minimally invasive procedures are surgical or therapeutic interventions performed using small incisions or catheter-based techniques to minimize trauma, shorten recovery time, and reduce complications. The growing adoption of minimally invasive surgeries is attributed to faster recovery, as these procedures involve smaller incisions, causing less tissue damage and promoting quicker healing. This enables patients to resume their daily activities sooner compared to traditional open surgeries, making it a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) facilitate minimally invasive procedures by enabling advanced techniques such as endovascular embolization, which employs catheters and image-guided interventions to decrease abnormal blood flow without the need for open surgery, resulting in lower risks, shorter recovery periods, and better patient outcomes. For example, in September 2023, according to the American Society of Plastic Surgeons, a US-based organization, a total of 25,442,640 cosmetic minimally invasive procedures were carried out, up from 23,672,269 procedures in 2022. This indicates a 7% growth in minimally invasive treatments for both genders in 2023. Thus, the rising preference for minimally invasive procedures is fueling the growth of the arteriovenous malformations market.

The rising investment in biotechnology is anticipated to drive the growth of the arteriovenous malformations market in the coming years. Biotechnology involves the use of biological processes, organisms, or systems to create products and technologies for healthcare. The surge in biotechnology investments is attributed to advancements in gene editing technologies such as CRISPR, which allow precise genetic modifications and foster innovations in medicine. Arteriovenous malformations (AVMs) contribute to biotechnology by improving medical imaging, gene therapy, and minimally invasive treatments, leading to biotechnology-based solutions like targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For example, in August 2024, according to The BioIndustry Association (BIA), a UK-based trade association for innovative life sciences and the biotech industry, the UK's life sciences and biotechnology sector achieved its strongest investment quarter since the pandemic, securing $2.55 billion in the first two quarters of 2024, surpassing the $2.32 billion raised in 2023. Consequently, the growing investment in biotechnology is fueling the expansion of the arteriovenous malformations market.

Major companies in the arteriovenous malformations market are concentrating on technological innovations, such as liquid embolic system procedural sets, to simplify treatment processes and enhance patient outcomes. The liquid embolic system procedural set is a pre-assembled, sterilized kit that includes all essential components for delivering liquid embolic agents to treat vascular abnormalities like arteriovenous malformations (AVMs). For example, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson & Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This set comes in two configurations and contains the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, improving procedure readiness for treating cerebral arteriovenous malformations (AVMs).

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation.

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arteriovenous malformations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the arteriovenous malformations market by increasing costs of imported neuroimaging equipment, embolization materials, surgical instruments, and interventional devices used in diagnosis and treatment. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported medical technologies, while Asia-Pacific faces higher procurement costs for advanced diagnostic systems. These tariffs are raising treatment costs and slowing technology upgrades. At the same time, they are encouraging domestic manufacturing of medical devices and regional innovation in neurovascular treatment solutions.

The arteriovenous malformations market research report is one of a series of new reports that provides arteriovenous malformations market statistics, including arteriovenous malformations industry global market size, regional shares, competitors with a arteriovenous malformations market share, detailed arteriovenous malformations market segments, market trends and opportunities, and any further data you may need to thrive in the arteriovenous malformations industry. This arteriovenous malformations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arteriovenous malformations are abnormal clusters of blood vessels that form direct links between arteries and veins, bypassing the normal capillary network. This interferes with normal blood circulation and oxygen delivery, which may result in various complications. Timely diagnosis and proper treatment are essential for controlling symptoms and minimizing the risk of severe complications.

The primary categories of arteriovenous malformations include true arteriovenous malformations, occult or cryptic lesions, cavernous malformations, venous malformations, hemangiomas, dural fistulas, and others. A true arteriovenous malformation is a congenital vascular abnormality marked by a direct connection between arteries and veins, bypassing the capillary network. Diagnostic approaches include physical examinations, brain imaging scans, and other methods. Treatment options include endovascular embolization and neurosurgical procedures, and these are applied across different age groups such as adult and pediatric patients. These services are utilized by various end users, including hospitals and clinics, research laboratories, and others.

The arteriovenous malformations market consists of revenues earned by entities by providing services such as minimally invasive embolization, post-procedure rehabilitation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The arteriovenous malformations market also includes sales of embolization devices, neurovascular catheters, liquid embolic agents, microsurgical instruments, and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.